Overview

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Status:
Recruiting
Trial end date:
2022-01-28
Target enrollment:
Participant gender:
Summary
Drug: Cabozantinib Drug: Pembrolizumab
Phase:
Phase 2
Details
Lead Sponsor:
University of South Alabama
Collaborator:
Exelixis
Treatments:
Pembrolizumab